GSK Abreva Ad Claims Lack Supporting Data – Lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Data from studies measuring the efficacy of GlaxoSmithKline's OTC cold sore treatment Abreva do not substantiate ad claims for the product, Merix Pharmaceutical alleges in a false advertising suit
You may also be interested in...
Merix/Glaxo Cold Sore Cold War Ends With Settlement
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation
Merix/Glaxo Cold Sore Cold War Ends With Settlement
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation
Merix/Glaxo Cold Sore Cold War Ends With Settlement
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation